Inquiry Basket
CAS No.: 1835759-78-8
Cat No.: BADC-01544
Purity: 95%
4.5 
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine is an alkyne-functionalized PEG ADC linker enabling bioorthogonal click chemistry conjugation. This linker improves conjugate stability and targeted payload delivery in antibody-drug conjugates.
Structure of 1835759-78-8
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine is a specialized ADC linker intermediate designed for advanced antibody-drug conjugate (ADC) construction and targeted bioconjugation applications. Combining a tetraethylene glycol (PEG4) spacer with a terminal alkyne and a hydroxylamine functional group, this linker facilitates efficient, site-specific conjugation of monoclonal antibodies and ADC cytotoxins. The PEG4 spacer enhances solubility, reduces steric hindrance, and improves pharmacokinetic properties of ADC payloads. In ADC linker design, this compound supports precise attachment of payloads while preserving antibody structure and functionality, enabling controlled intracellular release in tumor cells.
In payload conjugation applications, O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine is compatible with a variety of ADC cytotoxins, including DNA-targeting drugs, microtubule inhibitors, and other potent therapeutic payloads. The terminal hydroxylamine reacts efficiently with aldehyde-functionalized payloads, while the alkyne allows modular click chemistry strategies for flexible bioconjugation. Its PEG4 spacer enhances linker flexibility and aqueous solubility, enabling stable and homogeneous ADC construction. Researchers can use this intermediate to optimize linker length, improve intracellular payload delivery, and construct high-performance ADCs suitable for both preclinical studies and scalable production.
From an application perspective, O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine is extensively used in oncology-focused ADC research, targeted drug delivery systems, and protein bioconjugation experiments. Its combination of hydrophilic PEG spacer, terminal alkyne, and hydroxylamine functionality allows predictable, site-specific conjugation with minimal impact on antibody function. By integrating this intermediate into ADC linker design, developers can construct flexible, stable, and highly soluble ADC payload conjugates, supporting tumor-specific delivery, optimized pharmacokinetics, and enhanced performance in modern antibody-drug conjugate development.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01545 | O-(2-(2-(2-(Prop-2-yn-1-yloxy)ethoxy)ethoxy)ethyl)hydroxylamine | 1807537-27-4 |
What is the function of O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine in ADCs?
This linker introduces both a hydroxylamine functional group and a PEG chain, enabling site-specific conjugation with aldehyde-containing payloads. The PEG segment improves solubility and reduces aggregation of the resulting ADC.
9/3/2019
Dear team, how does O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine impact ADC solubility?
The tetraethylene glycol chain increases hydrophilicity, enhancing aqueous solubility of ADCs. This reduces aggregation tendencies during storage and administration, improving formulation stability and consistency.
29/8/2020
Dear team, what conjugation chemistries are compatible with O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine?
Its hydroxylamine group enables oxime ligation with aldehyde-modified payloads. The alkyne terminus allows click chemistry, providing versatile conjugation strategies for precise and efficient ADC assembly.
26/12/2018
Good afternoon! Can O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine be used with multiple payload types?
Yes, it supports conjugation with both small-molecule cytotoxins and imaging agents. Its PEGylated linker ensures proper spacing between antibody and payload, maintaining stability and functional activity.
28/6/2020
Dear team, what are the best practices for handling O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine to ensure stability and safety?
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine should be handled under inert atmosphere and stored at low temperatures to prevent oxidation or hydrolysis. Use of gloves and protective eyewear is recommended. Proper storage and handling maintain its hydroxylamine functionality for reliable bioconjugation reactions.
12/3/2019
— Dr. Matthew Green, Biochemist (UK)
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine allowed highly efficient alkyne conjugation.
26/12/2018
— Ms. Anna Weber, Senior Scientist (Germany)
Excellent solubility facilitated smooth multi-step synthesis.
12/3/2019
— Dr. Daniel Clark, ADC Development Scientist (USA)
Reproducible incorporation in click chemistry reactions was achieved.
28/6/2020
— Dr. Sophie Laurent, Medicinal Chemist (France)
Minimal side reactions and high yields improved overall synthesis efficiency.
9/3/2019
— Dr. Lucas Meyer, Chemist (Germany)
The reagent enabled creation of extended PEG linkers improving solubility.
— Dr. Laura Meyer, Medicinal Chemist (Germany)
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine was crucial for our conjugation experiments. BOC Sciences provided reliable quality and prompt delivery.
29/8/2020
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine
Required fields are marked with *
O-(3,6,9,12-Tetraoxapentadec-14-yn-1-yl)hydroxylamine
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
